Pdb43 Patient Reported Outcomes Are Superior in Patients With Type 2 Diabetes Treated With Liraglutide as Compared to Exenatide, When Added to Metformin, Sulfonylurea or Both

Schmidt, WE; Christiansen, JS; Hammer, Mette; Zychma, M; Buse, John B.

doi:10.1016/s1098-3015(10)73586-5

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 Liraglutide was superior to exenatide with respect to convenience, flexibility, and perceptions of hypoglycemia and hyperglycemia. 53 …”

Section: Impact On Patient-reported Outcomesmentioning

confidence: 99%

Liraglutide for the Treatment of Type 2 Diabetes

Peters

2013

American Journal of Therapeutics

View full text Add to dashboard Cite

This review updates the pharmacology, efficacy, safety, and tolerability of liraglutide, a glucagon-like peptide 1 (GLP-1) analog approved for the treatment of type 2 diabetes (T2DM) in January 2010. MEDLINE was searched (May 2009-January 1, 2011) for articles in English, using the terms liraglutide, NN2211, incretin mimetic, glucagon-like peptide (GLP)-1, and GLP-1 receptor agonist. Abstracts from key meetings (ADA 2009 and 2010, AACE 2010, EASD 2009, and EASD 2010) were also searched for relevant data. A GLP-1 analog with pharmacokinetic properties allowing once-daily administration via subcutaneous injection, liraglutide has shown clinical benefits when used as monotherapy or in combination. Liraglutide monotherapy has demonstrated efficacy in reducing hemoglobin A1c (A1C) and body weight, with low risk for hypoglycemic events. Liraglutide has also been studied in combination with metformin, glimepiride, and rosiglitazone for the treatment of T2DM. Extension studies within the Liraglutide Effects and Action in Diabetes clinical program have demonstrated the efficacy of liraglutide over 2 years of treatment. Overall, liraglutide has been shown to be well tolerated, with dose-dependent nausea, vomiting, and diarrhea being the most commonly reported adverse events in clinical trials. Extended dosing periods have demonstrated the durability of response of liraglutide with respect to glycemic control, lack of weight gain, and blood pressure benefits. Compared with exenatide and sitagliptin, liraglutide seems to offer greater improvements in A1C, fasting plasma glucose, and body weight. Adverse events commonly associated with liraglutide in clinical trials included nausea and hypoglycemia. Emerging data suggest that liraglutide may be a useful option for patients with T2DM.

show abstract

“…25 Liraglutide was superior to exenatide with respect to convenience, flexibility, and perceptions of hypoglycemia and hyperglycemia. 53 …”

Section: Impact On Patient-reported Outcomesmentioning

confidence: 99%

Liraglutide for the Treatment of Type 2 Diabetes

Peters

2013

American Journal of Therapeutics

View full text Add to dashboard Cite

show abstract

“…Among patients who failed to reach this target with exenatide, 25% achieved it after switching to liraglutide and had an HbA1c reduction of 0.7% [106]. Treatment satisfaction, as measured by the DTSQ, improved significantly among patients switched from exenatide to liraglutide (p = 0.0131) [107], in agreement with DTSQ results from the main study in which 94% of liraglutide‐treated patients expressed satisfaction with their treatment compared with 86% of those receiving exenatide (p = 0.0176) [107].…”

Section: Clinical Trials Comparing Glp‐1 Rasmentioning

confidence: 99%

Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents

Blonde

Montanya

2012

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

The two classes of incretin-related therapies, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have become important treatment options for patients with type 2 diabetes. Sitagliptin, saxagliptin, vildagliptin and linagliptin, the available DPP-4 inhibitors, are oral medications, whereas the GLP-1 RAs-twice-daily exenatide, once-weekly exenatide and once-daily liraglutide-are administered subcutaneously. By influencing levels of GLP-1 receptor stimulation, these medications lower plasma glucose levels in a glucose-dependent manner with low risk of hypoglycaemia, affecting postprandial plasma glucose more than most other antihyperglycaemic medications. Use of GLP-1 RAs has been shown to result in greater glycaemic improvements than DPP-4 inhibitors, probably because of higher levels of GLP-1 receptor activation. GLP-1 RAs can also produce significant weight loss and may reduce blood pressure and have beneficial effects on other cardiovascular risk factors. Although both classes are well tolerated, DPP-4 inhibitors may be associated with infections and headaches, whereas GLP-1 RAs are often associated with gastrointestinal disorders, primarily nausea. Pancreatitis has been reported with both DPP-4 inhibitors and GLP-1 RAs, but a causal relationship between use of incretin-based therapies and pancreatitis has not been established. In clinical trials, liraglutide has shown efficacy and tolerability and resulted in certain significant benefits when compared with exenatide and sitagliptin.

show abstract

“…Within the LEAD-6 study, patient reported outcomes were recorded in 379 patients using the Diabetes Treatment Satisfaction Questionnaire score (DTSQs). 44 It was observed that the highest treatment satisfaction was with liraglutide compared to exenatide (P  0.0001). Of interest within the questionnaire, liraglutide was superior to exenatide in respect to 'current treatment', 'convenience', 'flexibility', 'recommend' and 'continue'.…”

Section: Patient Reported Outcomesmentioning

confidence: 96%

Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives

Edavalath¹,

Stephens²

2010

PPA

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is a progressive disease associated with significant morbidity and mortality. There is good evidence that intensive glycemic control reduces the development and progression of complications in patients with diabetes. In order to achieve glycemic targets, patients often require a combination of oral therapy and/or insulin in addition to lifestyle modification. Unfortunately many currently available therapies for T2DM are associated with weight gain and hypoglycemia resulting in poor compliance and subsequent worsening glycemic control. Glucagon like peptide-1 (GLP-1) is an incretin hormone secreted from the small intestine that lowers fasting and postprandial glucose through multiple mechanisms including glucose-dependent insulin secretion, reduction of glucagon secretion, delaying gastric emptying and increased satiety. Liraglutide is a long acting GLP-1 mimetic that is administered once a day by subcutaneous injection and is now licensed for the treatment of T2DM. Phase 3 clinical trials have demonstrated beneficial effects on glycemic control and weight with liraglutide therapy. Within this article, we provide an overview of pharmacology, efficacy, safety and patient experience on liraglutide in the management of T2DM.

show abstract

Pdb43 Patient Reported Outcomes Are Superior in Patients With Type 2 Diabetes Treated With Liraglutide as Compared to Exenatide, When Added to Metformin, Sulfonylurea or Both

Cited by 3 publications

References 0 publications

Liraglutide for the Treatment of Type 2 Diabetes

Liraglutide for the Treatment of Type 2 Diabetes

Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents

Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives

Contact Info

Product

Resources

About